MAIA announces peer-reviewed publication validating second-gen ateganosine prodrugs

MAIA Biotechnology, Inc.

Data published in Nucleic Acids Research (Vol. 53, Issue 12, June 26, 2025) on novel telomere-targeting dinucleotide prodrugs.
Lead candidates MAIA-2022-12 and MAIA-2021-20 showed strongest in vivo anticancer efficacy and immune-memory responses.
Combination with immune checkpoint inhibitor yielded significantly lower IC50 and superior efficacy vs monotherapy.
Company plans to advance one candidate into human clinical trials after completing GLP-toxicity studies.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.